Navigation Links
Application of Hepatocyte Growth Factor - New Hope for Many Conditions
Date:12/2/2013

BEIJING, Dec. 2, 2013 /PRNewswire/ -- ReLife International Medical Center researches hepatocyte growth factors. HGF is a paracrine cellular growth, motility and morphogenic factor secreted by mesenchymal cells. By acting as a multi-functional cytokine, HGF is being applied in treatments for not only hepatic conditions but also many other diseases in nowadays due to its angionenic, anti-fibrotic and antiapoptosis actions. [1, 2]

Ischemic diseases  HFG can stimulate the migration, proliferation and neovascularization of vascular endothelial cells. In addition, HGF is capable of protecting the nerves cell by increasing neuronal survival and axonal regeneration. HGF has proven to be effective in gene therapy for limb ischemia conditions and myocardial ischemia. Decreasing of ulceration area and pain relief have been shown in patients with lower limb ischemia conditions after being treated with HGF. Combination of mesenchymal stem cells - MSCs with adenovirus carrying HGF can promote neovascularization in chronic ischemic myocardium, inhibit apoptosis and improve the cardiac functions.

Diabetes  HFG can inhibit the apoptosis of endothelial cells under hyperglycemic environment and promote the repair process of vascular endothelial cells, which is an ideal treatment for diabetic vascular complications. On the other hand, HGF can inhibit the fibrosis of renal interstitium of Diabetic Nephropathy. It can also promote MSCs to differentiate into islet cells in stem cell therapy.

Others  HFG is able to relieve neuron hypoxia injuries and promote neural stem cells to differentiate into neuronal cells. HGF can also protect human pulmonary microvascular endothelial cells and promote the repair of damage resulting from a pulmonary injury, etc.

With its multi-functional characteristics, HGF might have a bright future in the medical field.

[1] Azuma J, Taniyama Y, Takeya Y, et al. Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther, 2006, 13: 1206--1213

[2] Jayasankar V, Woo Y J, Pirolli T J, et al. Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure. J Card Surg, 2005, 20: 93--101


'/>"/>
SOURCE ReLife International Medical Center
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Applications due in December for Photonics Innovation Village
2. Mesenchymal Stem Cells - Advances & Applications 2013
3. Convey Computer to OEM Dell Servers to Accelerate Data Intensive Applications for Data Centers
4. Convey Computer Announces New Hybrid-Core Coprocessor to Accelerate Data-Intensive Applications
5. Biomarkers: Discovery Techniques and Applications - A Global Market Overview
6. Applications Due This Month for SPIE Startup Challenge at Photonics West 2014
7. MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of MCT-485, a Noncoding miRNA for Cancer Treatment
8. Advances for Food Safety, Energy, Security and More on the Program for SPIE Micro+Nano Materials, Devices, and Applications
9. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
10. CIRTEMO to Launch Multivariate Optical Element Platform for Neuroscience Applications
11. Tunisia Hosts First African Summer School on Optics and Applications to Sustainable Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... April 20, 2017 , ... Husson University will be ... growing body of knowledge during its Eighth Annual Research and Scholarship Day ... Darling Atrium. During the event, undergraduates, graduate students, and faculty members from all ...
(Date:4/20/2017)... ... April 20, 2017 , ... Parallel6™ , the leader in mClinical™ ... that they were named one of the 2017 Top 10 eClinical Trial Management ... the pharmaceutical industry. , “We take pride in honoring Parallel6 as one of the ...
(Date:4/20/2017)... -- For today, Stock-Callers.com redirects investors, attention to ... clinical research aimed at treating diseases and medical conditions. Under ... Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), and ZIOPHARM ... our complimentary research reports on these stocks now at: ... http://stock-callers.com/registration ...
(Date:4/19/2017)... ... April 18, 2017 , ... Optofluidics today announced ... comes after the company changed focus to making analytical tools for biopharmaceutical quality ... new technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart and David ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):